Supernus Pharmaceuticals | SUPN - Current Assets


Supernus Pharmaceuticals reported $711.21M in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Abbott USD 23.5B 1.02B Sep/2026
ANI Pharmaceuticals USD 902.82M 77.39M Sep/2026
Aurora Cannabis CAD 393.45M 4M Jun/2026
Bristol-Myers Squibb USD 29.77B 1.19B Sep/2026
Canopy Growth CAD 506.36M 23.1M Jun/2026
Cara Therapeutics USD 23.13M 2.2M Sep/2026
Corcept Therapeutics USD 533.87M 94.2M Sep/2026
Eisai JPY 866.82B 16.2B Sep/2026
Eli Lilly USD 65.26B 591M Sep/2026
Novo Nordisk DKK 208.7B 31.38B Jun/2026
Pacira USD 10.3B 9.68B Sep/2026
Perrigo USD 2.4B 49.7M Sep/2026
Pfizer USD 45.01B 3.65B Sep/2026
Supernus Pharmaceuticals USD 711.21M 12.28M Sep/2026
United Therapeutics USD 2.88B 603.5M Sep/2026
Xeris Pharmaceuticals USD 289.26M 14.51M Sep/2026